ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pitavastatin

Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.

Drug pagePitavastatin: every studyMany companies study it; this page follows only the 29 they lead. All 75 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 18, 200929 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kowaits history only180 open or runningphase 4since Dec 18, 2009Nov 4, 2005none ahead
JW Pharmaceuticalits history only80 open or runningphase 4since Mar 18, 2008Mar 18, 2008none ahead
Merck10 open or runningphase 1since Oct 12, 2017Oct 12, 2017none ahead
Orient Pharmaits history only10 open or runningphase 3since Oct 16, 2012Oct 16, 2012none ahead
Tai Tien Pharmaceuticalsits history only10 open or runningphase 3since Jun 29, 2011Jun 29, 2011none ahead

Also a collaborator on its studies: Orient Europharma, Kowa Pharmaceuticals America and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 12, 2017First study: phase 1 study in Renal InsufficiencyFirst studyNCT03311841 · 32 enrolled · United States

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03311841Renal Insufficiency · United States1CompletedAug 2, 201832

How it is read

Names in the registry

  • “Pitavastatin”, 18 entries
  • “pitavastatin”, 8 entries
  • “Pitavastatin (NK-104)”, 3 entries
  • “NK-104-CR”, 2 entries
  • “pitavastatin single dose combined with ceftobiprole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.